Trial Profile
A prospective and exploratory study of Apatinib Combined With TACE in the treatment of medium-advanced Hepatocellular Carcinoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 12 Jun 2018 New trial record